顺气通腑合剂对腹部术后患者胃肠运动功能的影响

目的 观察顺气通腑合剂对腹部手术后胃肠运动功能恢复的促进作用,并探究其作用机制。方法 将62例腹部手术患者随机分为治疗组和对照组,对照组患者按受术后常规治疗,治疗组患者加服顺气通腑合剂,连用3～5 d。观察两组术后肠鸣音恢复时间、首次排气时间、首次排便时间;并测定患者血浆胃动素（motilin,MTL）、P物质（substance P,SP）和生长抑素（somatostatin,SS）水平的变化。结果 治疗组患者肠鸣音恢复时间、首次排气时间、首次排便时间均明显少于对照组(P<0.05);治疗组患者术后MTL、SP含量均较治疗前显著升高（P<0.05）,SS水平较治疗前显著下降（P<0.05）;对照组治疗后SP水平较治疗前显著升高（P<0.05）。治疗组治疗后SP和MTL变化率显著大于对照组（P<0.05）,两组治疗后SS变化率比较,差异无统计学意义（P>0.05）。结论 顺气通腑合剂对腹部术后胃肠运动功能的促进作用与其调节血浆胃肠激素有关。     

胃宁合剂抗炎镇痛的药效学及急性毒性实验研究

目的 :探讨胃宁合剂抗炎镇痛的作用机制。方法 :检测胃宁合剂对冰乙酸致痛扭体小鼠的影响 ;对热板致痛小鼠的影响 ;对小鼠毛细血管通透性增高的影响 ;测小鼠一日最大耐受量。结果 :胃宁合剂对冰乙酸致痛扭体小鼠及热板致痛小鼠均有镇痛作用 ;能抑制小鼠腹腔注射冰乙酸所致的毛细血管通透性增高 ,有抗急性炎症作用 ;一日最大耐受量相当于临床用量的 12 0倍 ,提示临床用量在安全范围。结论 :胃宁合剂有抗炎、镇痛作用 ,与该方临床功效相符 ;临床用量在安全范围     

小儿健脾开胃合剂联合赖氨酸维B12颗粒治疗小儿厌食症的临床研究

目的研究小儿健脾开胃合剂联合赖氨酸维B_(12)颗粒治疗小儿厌食症的临床疗效。方法选取2017年12月—2018年12月青海省妇女儿童医院收治的80例厌食症患儿为研究对象,将所有患儿随机分为对照组和治疗组,每组各40例。对照组患儿口服赖氨酸维B_(12)颗粒,1～5岁,0.5袋/次,2次/d,6～12岁,1袋/次,2次/d;治疗组患儿在对照组治疗的基础上口服小儿健脾开胃合剂,10 mL/次,2次/d。两组患儿持续治疗30 d。观察两组的临床疗效,比较两组的微量元素、生化指标水平。结果治疗后,对照组和治疗组的总有效率分别为82.50%、95.00%,两组比较差异有统计学意义(P0.05)。治疗后,两组患儿铁、钙和锌水平均显著升高,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患儿铁、钙和锌水平均明显高于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患儿血红蛋白(Hb)、血清淀粉酶(AMS)、血清铁蛋白(SF)水平均显著升高,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患儿Hb、AMS、SF水平明显高于对照组,两组比较差异有统计学意义(P0.05)。结论小儿健脾开胃合剂联合赖氨酸维B_(12)颗粒治疗小儿厌食症具有较好的临床疗效,能改善患儿贫血症状,调节血清微量元素水平,具有一定的临床推广应用价值。     

生血宝合剂联合利妥昔单抗治疗自身免疫性溶血性贫血的临床研究

目的研究生血宝合剂联合利妥昔单抗注射液治疗自身免疫性溶血性贫血的临床疗效。方法选取2017年12月—2018年12月绵阳市中心医院收治的80例自身免疫性溶血性贫血患者为研究对象,将所有患者随机分为对照组和治疗组,每组各40例。对照组患者静脉注射利妥昔单抗注射液,100 mg次加入到5%葡萄糖溶液中,稀释到1 mg/mL,1次/周;治疗组在对照组基础上口服生血宝合剂,15 mL/次,3次/d。两组患者持续治疗30 d。观察两组的临床疗效,比较两组的生化指标水平、免疫功能指标。结果治疗后,对照组和治疗组的总有效率分别为77.50%、92.50%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者红细胞计数(RBC)和血红蛋白(HGB)水平均显著升高,网织红细胞百分率(Ret)水平显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组患者生化指标水平明显优于对照组,两组比较差异有统计学意义(P0.05)。治疗后,治疗组患者CD3+、CD4+、CD4+/CD8+、NK水平均显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组免疫功能指标水平显著高于对照组,两组比较差异有统计学意义(P0.05)。结论生血宝合剂联合利妥昔单抗注射液治疗自身免疫性溶血性贫血具有较好的治疗效果,可改善免疫功能,调节RBC、HGB、Ret水平,具有一定的临床推广应用价值。     

针刺廉泉穴配合利咽合剂治疗脑卒中吞咽功能障碍临床观察

目的:观察针刺廉泉穴配合利咽合剂治疗脑卒中吞咽功能障碍的临床疗效。方法:100例按照随机数字表法分为对照组和观察组各50例。两组均用常规吞咽功能训练,并针刺廉泉穴,观察组加用利咽合剂,治疗时间为8周。结果:治疗后观察组VFSS评分和MMASA评分高于对照组(P<0.05),洼田饮水评分低于对照组(P<0.05)。观察组总有效率94.78%高于对照组78.00%。结论:针刺廉泉穴联合利咽合剂治疗脑卒中吞咽功能障碍能够改善症状,提高疗效。     

蛭草茶合剂对糖尿病小鼠视网膜Müller细胞的保护作用及炎症因子表达的影响

目的:观察蛭草茶合剂对糖尿病小鼠视网膜Müller细胞的保护作用及对炎症因子表达的影响。方法:健康清洁级雄性C57BL/6J小鼠75只,采用随机数字表法随机分为正常对照组、糖尿病组、低浓度蛭草茶合剂治疗组(低浓度治疗组)、中浓度蛭草茶合剂治疗组(中浓度治疗组)、高浓度蛭草茶合剂治疗组(高浓度治疗组),每组15只。糖尿病组、不同浓度治疗组小鼠按60 mg/kg剂量腹腔注射STZ诱导糖尿病动物模型。建模后4周,低浓度治疗组、中浓度治疗组、高浓度治疗组大鼠分别按30、60、120 ml/kg的浓度行蛭草茶合剂灌胃治疗。每两周测定各组小鼠体重及血糖。第8周后,采用Western blot检测各组小鼠视网膜Müller细胞中胶质纤维酸性蛋白(GFAP)表达;免疫荧光检测GFAP、谷氨酰胺合成酶(GS)表达;实时荧光定量PCR(RT-qPCR)、ELISA分别检测VEGF、TNF-α、IL-1β、IL-6 mRNA和蛋白表达。组间比较采用单因素方差分析。结果:糖尿病组小鼠体重较正常对照组降低,血糖升高;不同浓度治疗组小鼠血糖呈降低趋势。与正常对照组比较,糖尿病组小鼠视网膜Müller细胞GFAP蛋白表达升高(t=38.318,P<0.001),GS蛋白表达降低(t=29.737,P<0.001),差异有统计学意义;与糖尿病组比较,低浓度治疗组、中浓度治疗组、高浓度治疗组小鼠Müller细胞GFAP蛋白表达下降(t=13.677、19.387、16.305,P<0.05),GS蛋白表达升高(t=5.170、19.399、6.705,P<0.05),差异均有统计学意义。糖尿病组小鼠视网膜Müller细胞VEGF、TNF-α、IL-1β、IL-6 mRNA和蛋白表达均升高,不同浓度治疗组均降低。结论:蛭草茶合剂可降低糖尿病小鼠血糖,减轻糖尿病视网膜炎症反应。     

Influence of the spray adjuvant on the toxicity effects of a glyphosate formulation

In the present study, the influence of the spray adjuvant on the toxicity effects of a glyphosate formulation was examined in HEp-2 cell line. We determined the median lethal concentration (LC₅₀) of Atanor® (glyphosate formulation), Impacto® (spray adjuvant) and the mixture of both agrochemicals. We also compared the toxicities of the pesticides individually and in mixture and we analyzed the effects on oxidative balance from each treatment.Our results showed that all the agrochemicals assayed induce dose and time-dependent cytotoxicity and that the toxicity of Impacto® with Atanor® (mixture) was additive on HEp-2 cell line.All the agrochemicals assayed produced an increase in catalase activity and glutathione levels, while no effects were observed for superoxide dismutase and glutathione-S-transferase activities. We found an important increase in ROS production in cells treated with Atanor® and mixture. Besides, all the agrochemicals used triggered caspase 3/7 activation and hence induced apoptosis pathway in this cell line. In conclusion, our results demonstrated that the addition of adjuvant to glyphosate formulation increase the toxicity of the mixture in cell culture. Furthermore, cell culture exposed to agrochemical mixture showed an increased ROS production and antioxidant defenses.     

10-year risk for atherosclerotic cardiovascular disease and coronary heart disease among Korean adults: Findings from the Korean National Health and Nutrition Examination Survey 2009–2010

Background

This study examined the distribution of the 10-year risk for development of atherosclerotic cardiovascular disease (ASCVD) and coronary heart disease (CHD), and the proportion of participants eligible for lipid management, in the Korean population.

Methods

The risk was estimated using the Pooled Cohort Equations for non-Hispanic Whites and the Adult Treatment Panel (ATP) III equations. Eligibility for lipid-lowering treatment was assessed using the American College of Cardiology/American Heart Association Blood Cholesterol Guideline and the ATP III recommendation. Complex sampling design and area under the receiver operator characteristic curve (AUC) were used.

Results

Among 7594 ASCVD-free Korean adults, aged 40–79 years, 31.3% (men, 44.1%; women, 19%) had a 10-year risk for an ASCVD event of ≥ 7.5%, and 27.1% (men, 39.4%; women, 15.2%) had a 10-year risk for a CHD event of ≥ 10%. These proportions differed according to age groups, ranging from 6.1 to 91.9% and 8.7 to 58.7% for patients in their 40s–70s, using the ASCVD and CHD risk estimations, respectively. Overall, 78.7% of individuals remain in the same risk stratum. Those eligible for lipid management included 32.8% of the participants using the ACC/AHA Guideline and 11.9% of those using the ATP III recommendation. In discriminating ASCVD, AUCs for the ASCVD risk assessment method and the CHD risk assessment method were 0.70 and 0.64, respectively (P < 0.001).

Conclusions

The distribution of 10-year ASCVD and CHD risk was different according to the risk assessment methods.     

中药复方合剂抗甲型H1N1流感病毒活性的实验研究

目的:观察中药复方合剂对甲型流感病毒A/PR/8/34(H1N1)的抑制作用.方法:采用鸡胚法检测药物对鸡胚的最大无毒限量和半数鸡胚感染量(EID50),通过中药复方合剂对病毒的直接作用、预防作用和治疗作用,观察鸡胚的存活率和测定鸡胚尿囊液血凝滴度.结果:中药复方合剂对鸡胚最大安全浓度为500 mg/mL,半数鸡胚感染...     

Characteristic chemical profile of Juhe Fang extract with lipid-lowering properties

ObjectiveThe objective of this study was to verify the lipid-lowering effect of Juhe Fang extract (JHFE) and to determine its characteristic chemical profile in vitro and in vivo.MethodsA hyperlipidemia model was established by feeding mice a high-fat diet (HFD). After treatment for 30 days, serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were measured with an automatic biochemistry analyzer. The components from JHFE obtained from in vivo and in vitro experiments were investigated using an UPLC-Q Exactive-Orbitrap MS/MS.ResultsThe TC, TG, and LDL-C in the serum significantly decreased and the HDL-C significantly increased after JHFE treatment. A total of 95 compounds from JHEF including 15 phenolic acids (PA), 4 phenylethanoid glycosides (PG), 24 flavonoids (F), 14 triterpenoids (T), 10 diterpenoid glycosides (D), 18 alkaloids (A) and 10 others (O) were identified. Trigonelline was discovered for the first time in a herbal medicine of Juhe Fang. Furthermore, 68 compounds were identified in vivo including 28 prototype compounds and 40 metabolites. The metabolic characteristics of these components were revealed including identification of new metabolites of 4-hydroxyphenyl ethyl-8-O-[α-L- arabinopyranosyl-(1 → 6)]-β-D-glucopyranoside (PEG) and lirinidine. A total of 43 components from JHFE were absorbed and/or metabolized. The contribution rate of each type of chemical component from JHFE to its lipid-lowering effect from high to low were A, F, PG, PA, D and T.ConclusionThe results of this study showed that JHFE demonstrated a significant lipid-lowering effect in a high-fat diet (HFD)-induced hyperlipidemia mouse model. Specific types of PA, PG, F, D, T and A formed the pharmaceutical architecture of the lipid-lowering effect of JHFE. This study should prove useful for clarifying the components responsible for the lipid-lowering effect of JHFE and provide a basis for precision quality control research.